Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-0325901 in Adolescents and Adults With NF1-Associated Plexiform Neurofibromas
NCT02096471Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirdametinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by University of Alabama at Birmingham. Primary endpoint: Percent of Participants With a 20% or More Change in Target Tumor Volume at 24 months. Started Jun 2014; status: completed.
02
Drugs
mirdametinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT02096471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096471.